Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

FreeStyle Libre Glucose Monitoring System in Pediatric Populations

24 de enero de 2019 actualizado por: Abbott Diabetes Care

FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations

This study is a non-randomized, single-arm, multi-center study that is designed to evaluate the safety and effectiveness of the FreeStyle Libre Flash Glucose Monitoring Systems in pediatric populations.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

Up to 85 subjects will be enrolled at up to four (4) clinical research sites in the United States. Subjects will wear two Sensors. Each Sensor will have a paired Reader that will be given to the subject. All Readers will be masked during the study (i.e. subjects will not be able to view glucose results obtained from the Sensor on the Reader screen). Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader. Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test. Subjects will be instructed to report any problems with the device. Subjects will make four (4) to five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.

Tipo de estudio

De observación

Inscripción (Actual)

63

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Santa Barbara, California, Estados Unidos, 93105
        • Sansum Diabetes Research Institute
      • Walnut Creek, California, Estados Unidos, 94598
        • Diablo Clinical Research
    • Idaho
      • Idaho Falls, Idaho, Estados Unidos, 83404
        • Rocky Mountain Diabetes & Osteoporosis Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Subjects aged 6-17 years, with type 1 or type 2 diabetes who currently perform capillary blood glucose (BG) testing at least four (4) times a day.

Descripción

  • Inclusion Criteria:

    • Subject must be at least 6 years of age.
    • Subject must weigh at least 26 kg (57.2 lbs.).
    • Subject must have a diagnosis of type 1 or type 2 diabetes mellitus
    • Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
    • Subject must be currently performing at least four (4) capillary blood glucose tests per day.
    • Subject is willing to perform a minimum of 4 finger sticks per day during the study.
    • Subject is willing to allow medical personnel to insert at IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.
    • Subject and/or guardian must be able to read and understand English.
    • In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
    • Subject must be available to participate in all study visits.
    • Subject must be willing and able to provide written signed and dated informed assent when appropriate.
    • Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.
  • Exclusion Criteria:

    • Subject is 18 years of age or older.
    • Subject weighs less than 26 kg (57.2 lbs.).
    • Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
    • Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
    • Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
    • Subject is currently participating in another clinical trial.
    • Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects.
    • Subject is anemic, defined as having hemoglobin levels below 11.5 g/dL for subjects aged 6-11 years old, less than 12.0 g/dL for subjects aged 12-15 years old, less than 12.0 g/dL for females aged 15-17 and less than 13.0 g/dL for males aged 15-171, or as determined by investigator.
    • Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
    • Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
FreeStyle Libre Flash Glucose Monitoring System Performance
Periodo de tiempo: up to 14 days
System performance will be characterized with respect to YSI reference venous plasma sample measurements. Point accuracy of the system will be evaluated as the proportion of System readings that are within ±20% of the YSI reference value for YSI glucose levels ≥ 80 mg/dl and within ±20 mg/dl for YSI glucose levels <80 mg/dl.
up to 14 days
FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
Periodo de tiempo: up to 45 days
System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.
up to 45 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Shridhara Alva, PhD, Abbot Diabetes care inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de abril de 2018

Finalización primaria (Actual)

3 de julio de 2018

Finalización del estudio (Actual)

3 de julio de 2018

Fechas de registro del estudio

Enviado por primera vez

4 de abril de 2018

Primero enviado que cumplió con los criterios de control de calidad

17 de abril de 2018

Publicado por primera vez (Actual)

18 de abril de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de enero de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

24 de enero de 2019

Última verificación

1 de abril de 2018

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ADC-US-VAL-18172

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Diabetes mellitus

Suscribir